EGFR-antibody-nanostructures carrying KRAS-siRNA, but not control-siRNA treated cells showed marked reduction of KRAS protein expression levels in EGFR-positive NSCLC cell lines A549 and A427 as determined by Western blot analysis (Fig. 5B). This evidence concerns the gene KRAS and non-small cell lung carcinoma.